Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.32 |
| ▸ | CAPN9 | O14815 | 1/20 | 0.32 |
| ▸ | CTSB | P07858 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.32 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6983402 | 0.81 | NPC1 (0.54) | GAAPOLBNPSR1ALDH1A1KMT2A | |
| SCHEMBL6985573 | 0.78 | CASP1 (0.46) | GAANPSR1SMN1; SMN2ALDH1A1CAPN1 | |
| SCHEMBL6981304 | 0.75 | CNR1 (0.44) | SMN1; SMN2KMT2A | |
| SCHEMBL6981146 | 0.75 | ALDH1A1 (0.45) | GAAL3MBTL1POLBSMN1; SMN2ALDH1A1 | |
| SCHEMBL6979222 | 0.75 | CAPN1 (0.47) | GAACAPN1CAPN9CTSBMAPK1 | |
| SCHEMBL6981707 | 0.75 | SMN1; SMN2 (0.43) | L3MBTL1NPSR1SMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL6984525 | 0.74 | GFER (0.46) | L3MBTL1NPSR1ALDH1A1MAPK1KMT2A | |
| SCHEMBL6985160 | 0.73 | MEN1 (0.48) | NPSR1SMN1; SMN2ALDH1A1MAPK1KMT2A | |
| SCHEMBL6978511 | 0.73 | NPC1 (0.54) | GAAPOLBNPSR1ALDH1A1KMT2A | |
| SCHEMBL8617486 | 0.65 | CAPN1 (0.33) | GAAL3MBTL1SMN1; SMN2ALDH1A1CAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6551999-B1 | For therapy and prophylaxis of angiogenesis associated with wound healing, inflammation, growth of tumor and the like; angiogenesis as seen in diabetic retinopathy, prematurity retinopathy, retinal venous occlusion, metastasis of tumors | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2003-04-22 | — | — | US | disclosed |
| EP-0771565-B1 | Angiogenesis inhibitor | SENJU PHARMA CO (JP) | 2003-01-02 | — | — | EP | disclosed |
| US-6214800-B1 | ANGIOGENESIS INHIBITORS | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2001-04-10 | — | — | US | disclosed |
| US-6057290-A | ADMINISTERING A CYSTEINE PROTEASE INHIBITOR TO A PATIENT FOR INHIBITING ANGIOGENESIS | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2000-05-02 | — | — | US | disclosed |
| EP-0928786-A1 | Angiogenesis inhibitor | Senju Pharmaceutical Co., Ltd. (JP) | 1999-07-14 | — | — | EP | disclosed |
| EP-0927716-A1 | Angiogenesis inhibitor | Senju Pharmaceutical Co., Ltd. (JP) | 1999-07-07 | — | — | EP | disclosed |
| EP-0838460-A1 | PIPERAZINE DERIVATIVES AND USE OF THE SAME | Senju Pharmaceutical Co., Ltd. (JP) | 1998-04-29 | — | — | EP | disclosed |
| EP-0771565-A2 | Angiogenesis inhibitor | Senju Pharmaceutical Co., Ltd. (JP) | 1997-05-07 | — | — | EP | disclosed |